INVITED REVIEW
P2 receptors in regulation of renal microvascular function

Edward W. Inscho

Department of Physiology, Tulane University School of Medicine, New Orleans, Louisiana 70112, and Department of Physiology, Medical College of Georgia, Augusta, Georgia 30912-3000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

In the last 10-15 years, interest in the physiological role of P2 receptors has grown rapidly. Cellular, tissue, and organ responses to P2 receptor activation have been described in numerous in vivo and in vitro models. The purpose of this review is to provide an update of the recent advances made in determining the involvement of P2 receptors in the control of renal hemodynamics and the renal microcirculation. Special attention will be paid to work published in the last 5-6 years directed at understanding the role of P2 receptors in the physiological control of renal microvascular function. Several investigators have begun to evaluate the effects of P2 receptor activation on renal microvascular function across several species. In vivo and in vitro evidence consistently supports the hypothesis that P2 receptor activation by locally released extracellular nucleotides influences microvascular function. Extracellular nucleotides selectively influence preglomerular resistance without having an effect on postglomerular tone. P2 receptor inactivation blocks autoregulatory behavior whereas responsiveness to other vasoconstrictor agonists is retained. P2 receptor stimulation activates multiple intracellular signal transduction pathways in preglomerular smooth muscle cells and mesangial cells. Renal microvascular cells and mesangial cells express multiple subtypes of P2 receptors; however, the specific role each plays in regulating vascular and mesangial cell function remains unclear. Accordingly, the results of studies performed to date provide strong support for the hypothesis that P2 receptors are important contributors to the physiological regulation of renal microvascular and/or glomerular function.

extracellular nucleotides; microcirculation; afferent arteriole; calcium signaling; mesangial cells; diadenosine polyphosphates; kidney; purinoceptors


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

P2 RECEPTORS ARE EMERGING as important elements by which vascular responses to physiological and pathophysiological stimuli are mediated and maintained (1, 4, 20, 26, 30, 33, 64, 76, 83, 92, 94, 111, 116, 135). Development of this field of study has been slow due to the lack of selective probes with which to manipulate receptor activation and signaling. However, in recent years, significant advances have been made, in part, through the development of more selective investigational tools, such as expression cloning and knockout models (34, 70, 108, 135). Application of these approaches has clarified our understanding of the pharmacology of P2 receptors. However, determination of the specific roles P2 receptors play in mammalian physiology or pathophysiology still remains to be established.

As interest in P2 receptor physiology has grown, so has interest in the role P2 receptors play in the physiology and pathophysiology of renal function. With this renewed interest has come a new appreciation for the roles extracellular adenine nucleotides, like ATP, can play in regulating or modulating renal function. In the last 5 years, investigators have provided compelling evidence that extracellular nucleotides, working through activation of P2 receptors, have a significant impact on renal microvascular function, mesangial cell function, and renal epithelial transport. The latter concept is the focus of a companion review in the present issue of this journal (150). P2 receptor activation has been implicated in regulating preglomerular resistance and in mediating renal microvascular autoregulatory behavior. Locally released ATP has a direct paracrine and/or autocrine effect, modulating renal epithelial transporters and tubular epithelial channels to influence tubular fluid composition. Although the specific roles for extracellular nucleotides and their receptors in the kidney have not been firmly established, it is clear that locally released ATP may play a significant role in the regulation of renal hemodynamics and tubular function. The purpose of this review is to summarize the present literature pertaining to the effect of P2 receptor activation on renal microvascular function and to detail the signal transduction mechanisms involved.


    PURINOCEPTOR CLASSIFICATION
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

Purinoceptors are membrane-bound receptors that are divided into two distinct families These families are summarized in Fig. 1 (1, 4, 20, 30, 56, 57, 64, 92, 116, 118, 120, 135). P1 receptors respond to adenosine and AMP and are further divided into four major subtypes, identified as A1, A2A, A2B and A3 receptors (56, 57, 89, 118, 120, 135). A1 receptors are thought to induce vasoconstriction by inhibiting adenylate cyclase activity, thus reducing the formation of cAMP in vascular smooth muscle. A2A and A2B receptors evoke vasodilation by stimulating adenylate cyclase activity and increasing the formation of cAMP in vascular smooth muscle. The more recently described A3 receptors are thought to exert their physiological effects through activation of calcium signaling pathways and perhaps inhibition of cAMP accumulation (88, 89, 135).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1.   P1 and P2 receptor classification and the signaling mechanisms thought to be involved. PLC, phospholipase C; GP, G proteins; R, receptor; VOC, voltage-operated calcium channel; ROC, receptor-operated calcium channel; GI, inhibitory G proteins; GS, stimulatory G proteins; Ad Cyc, adenylate cyclase.

Functional effects of A1 and A2 receptors have been described in the kidney and include direct actions on preglomerular and postglomerular microvascular function (2, 5, 22, 27, 36, 61, 83, 91, 98, 99, 104, 105, 109, 124, 133, 158, 172), protection from ischemic damage (37, 38, 50), endotoxic shock (115), renin secretion (66, 99, 110, 122, 124, 143, 153), and in mediating autoregulatory adjustments in preglomerular resistance (66, 121, 132, 143, 162). The role of A3 receptors in the kidney remains unclear (107).

P2 receptors (Fig. 1) were originally described by Burnstock (18, 19) as purinergic receptors, reflecting the fact that the original description pertained to the release of ATP as a neurotransmitter from peripheral sympathetic nerves (18, 19). Later, the term "P purinergic receptor" was revised to "P purinoceptor," and the nomenclature for identification of P1 and P2 receptors was standardized to "P2 receptors" by the International Union of Pharmacology (55, 56). Presently, P2 receptors are divided into two major families, labeled P2X and P2Y (Figs. 1 and 2), based on the facts that distinct genes code for these receptors, there are marked differences in receptor structure between the two families, and unique signal transduction pathways are invoked after receptor activation (1, 4, 20, 30, 55, 56, 64, 92, 116, 135).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 2.   P2 receptor classification and the calcium signaling mechanisms thought to be involved. This scheme is compiled from several recent reviews (1, 39, 55, 116, 135). IP3, inositol 1,4,5-triphosphate.

P2X receptors (Fig. 2) comprise multiple subtypes that can form homomeric complexes or exist as heteromeric complexes that combine with other P2X receptor subtypes. The latter results in hybrid receptors that exhibit modified pharmacological, biophysical, and electrophysiological properties compared with those of each constituent monomeric form of the receptor (1, 4, 30, 48, 64, 92, 116, 135). A single P2X receptor possesses two membrane-spanning domains linked by a large extracellular loop and with the NH2- and COOH-terminal tails exposed to the cytoplasm. These receptors function as ligand-gated channels and can be profoundly influenced by the presence of cations (48, 135, 163). For example, high concentrations of Mg2+ or Ca2+ generally inhibit P2X receptor currents, whereas cations like Zn2+, Cu2+, and Cd2+ can either potentiate or inhibit cation currents in a P2X receptor-specific manner (1, 4, 30, 64, 92, 116, 135). On activation by ATP, the nonselective cation channel, which is intrinsic in the receptor structure, is opened, allowing Na+ and Ca2+ to pass from the extracellular fluid to the intracellular cytoplasm (39, 42, 135). Potassium ions can also pass through this channel (39, 42, 135). Presently, there are approximately seven P2X receptor subtypes (P2X1-7) that have been described on the basis of pharmacological assessment of receptor activity and of receptor cloning and expression studies (48, 116, 135). Investigators have also reported the cloning of the gene for P2XM and P2X8 receptors that are derived from skeletal muscle; however, more work needs to be completed before their places in the P2X receptor family can be determined (11, 67, 112).

A splice variant of the P2X2 receptor isolated from the rat cerebellum has also been described (16, 135, 151). This receptor differs from other P2X2 receptors by the absence of a 69-residue sequence from the COOH terminal of the receptor protein. The role of this receptor is presently unknown. However, because of the potential physiological alterations that splicing could represent, more attention should be focused on the in vivo study of these receptors rather than relying on data obtained from reconstituted receptor models.

As mentioned above, it has recently been determined that some P2X receptors can form heteromultimers by combining with other P2X subtypes (48, 116). On the basis of experiments conducted in heterologous expression systems, receptor pairs formed from P2X1 and P2X5 (P2X1/P2X5), P2X2 and P2X3 (P2X2/P2X3), and P2X4 and P2X6 (P2X4/P2X6) receptors have been described. P2X7 receptors do not coimmunoprecipitate with any other known P2X receptor; however, P2X5 receptors coimmunoprecipitate with all other known P2X receptor subtypes (116). Although the physiological role of the heteromeric P2 receptors remains to be determined, the potential for adding a new level of sophistication and selectivity to the regulatory influences of P2 receptors is quite interesting, because the behavior of each heteromeric receptor is modified according to the respective pharmacological properties of the individual subunits. For example, homomeric P2X1 receptors are activated by alpha ,beta -methylene-ATP and desensitize rapidly, and P2X5 receptors are insensitive to alpha ,beta -methylene-ATP. In contrast, the P2X1/P2X5 heteromer exhibits a sustained current in response to alpha ,beta -methylene-ATP that does not readily desensitize (116). The unique combination of properties that can be achieved through the formation of heteromeric P2X receptors confers potentially new levels of physiological or pathophysiological control that still need to be elucidated.

P2Y receptors (Fig. 2) are composed of seven transmembrane-spanning domains and are regulated by G proteins (1, 4, 32, 97, 135). In most systems, activation of P2Y receptors is associated with activation of phospholipase C and the subsequent mobilization of calcium from inositol 1,4,5-triphosphate (IP3)-sensitive intracellular stores. ATP has also been reported to stimulate cAMP formation in some cell types through a variety of mechanisms and intermediates (32). For example, published reports indicate that P2 receptor stimulation can induce cAMP accumulation through adenosine-mediated A2 receptor activation after ATP hydrolysis and through the autocrine actions of P2 receptor-mediated prostaglandin E2 formation (32). The P2Y11 receptor has been suggested to couple directly to both phospholipase C and adenylate cyclase in Chinese hamster ovary cells (31, 32). The mammalian family of P2Y receptors includes the P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptor subtypes (Fig. 1) on the basis of responses to pharmacological agonists and antagonists and from receptor cloning and expression studies. Other putative P2Y receptors have been described in other species or cell types; however, verification of the receptor structures as that of unique P2Y receptors remains to be established (32, 135).


    P2 RECEPTOR AGONISTS AND ANTAGONISTS
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

Rapid advances in the field of P2 receptor pharmacology and physiology have been hampered by the lack of selective pharmacological tools. Ralevic and Burnstock (135) have compiled an excellent review of the tools presently in use as P2 receptor agonists and antagonists. In their description, they highlight the primary uses of these compounds, discuss the utility of these compounds against different P2 receptors, and indicate the limitations each compound presents. None of the agonists or antagonists presently in use discriminates very definitively between P2X and P2Y receptors. This leads to considerable confusion in the pharmacological characterization of P2 receptors from one investigator to the next, and from one tissue or cell type to the next. Nevertheless, some aspects of P2 receptor pharmacology can be deciphered by using these probes. Some of the most common agonists used are alpha ,beta -methylene-ATP and beta ,gamma -methylene-ATP, which are stable analogs of ATP. These agents are considered essentially inactive on P2Y receptors but exhibit fairly high selectivity for P2X receptors, in particular, the P2X1 and P2X3 receptor subtypes. In contrast, P2Y receptor-mediated responses can best be ascertained by using ADP, ADPbeta S, and UTP, which are weakly active or nearly inactive at P2X receptors. It is essential to remember, however, that because a significant lack of receptor subtype specificity exists with some agonists, cautious interpretation of data obtained with these probes is important.

P2 receptor antagonists should also be used with careful consideration of their limitations (135). Some of the most commonly used antagonists that are reasonably selective for P2 receptors, but do not readily discriminate between P2X and P2Y subtypes, include suramin, a symmetrical 3'-urea of 8-(benzamido)naphthalene-1,3,5-trisulfonic acid that is a derivative of suramin, pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid (PPADS), reactive blue 2, and reactive red. Antagonists with some specificity for P2X receptors include 8, 8'-[carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino)]bis(1,3,5-naphthalene- trisulfonic acid) and pyridoxal phosphate-6-azophenyl-2',5'-disulfonic acid (iso-PPADS). The interested reader is referred to the review by Ralevic and Burnstock (135) for a more thorough discussion of these agents.


    P2 RECEPTOR DISTRIBUTION WITHIN THE KIDNEY
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

There are numerous reports describing the expression and distribution of P2 receptors within the kidney or in renal tissues (3, 24-26). Although this review will not provide a comprehensive listing of these reports, it will endeavor to provide a reasonable representation of the ubiquitous expression of P2 receptors by different segments of the nephron and renal vasculature. P2 receptors are expressed on various segments of the renal vasculature (3, 10, 25, 44, 77, 101, 102, 169), microvasculature (3, 25, 61, 80, 83, 85, 171), glomeruli (17, 24, 72, 125, 126), and cells of the glomerular mesangium (59, 62, 63, 71, 73, 96, 128, 129, 131, 139, 146, 148, 155). In addition, P2 receptors have been shown to be expressed by proximal tubular epithelial cells (3, 23, 41, 90, 156, 175, 176), distal tubule cells (3, 9, 136), and loop of Henle cells and collecting duct cells (3, 8, 24, 87, 95, 123, 154, 156). For a more thorough discussion of this subject, readers are referred to the review by Schwiebert and Kishore (150) that appears in this issue of the journal. The P2X and P2Y receptor families are present on renal tissue, and some cells may express receptors from both families. For example, the vascular smooth muscle of afferent arterioles appears to express both P2X and P2Y receptors (80, 82). Investigations continue in an effort to establish the role that P2 receptors play in regulating renal vascular and tubular function. Those investigations have resulted in the emergence of many interesting possibilities for P2 receptor involvement in the regulation of renal microvascular function, glomerular hemodynamics, renal tubular function, and even in the regulation of urinary bladder function (26). The remainder of this review will focus on the renal microvascular effects of P2 receptor activation and discuss the possible role P2 receptors may play in the physiology of renal microvascular control.


    RENAL VASCULAR RESPONSE TO ATP
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

ATP concentrations in human arterial and venous plasma have been measured to be ~0.19 (0.38 µM) and 0.7 µg/ml (1.38 µM), respectively (53, 54). Much of the ATP could derive from red blood cells (35), endothelial cells (12, 13, 127), or platelets (6, 54). The interaction of circulating ATP with endothelial or vascular smooth muscle cells could play an important role in the regulation of vascular tone (35, 43, 49, 97). Exposure of renal microvascular smooth muscle to extracellular nucleotides can occur by administration of ATP into the vascular lumen. Alternatively, it can occur by direct application of ATP to the exposed vascular smooth muscle from the adventitial surface. Intrarenal infusion of ATP will deliver it directly into the vascular space and will result in its interaction with the endothelium before gaining access to the underlying vascular smooth muscle cells. Interaction of ATP with endothelial P2 receptors can result in the generation of endothelium-derived vasoactive factors that can influence the renal microvascular response. Adventitial administration allows the nucleotide to interact directly with receptors on the vascular smooth muscle cells. The order of the interaction may be an important contributor to the overall renal hemodynamic response to P2 agonists.

The impact of infused ATP or P2 agonists on renal blood flow or renal perfusion pressure is dependent on a number of factors, including the species being studied, the type of agonist infused, the ambient vascular tone, and the experimental approach being used. Infusion of ATP directly into the renal artery of the isolated perfused rat kidney evokes vasoconstriction under basal tone conditions and both vasoconstriction and vasodilation when renal vascular resistance is elevated (44, 49, 167, 168). At basal tone, infused ATP or the P2X agonist alpha ,beta -methylene-ATP induces a sustained concentration-dependent vasoconstriction (28, 44, 49, 167, 168); however, ATP-mediated responses observed in kidneys perfused at high tone are less consistent. Eltze and Ullrich (44) increased renal vascular resistance with norepinephrine and reported that infusion of the P2X agonist alpha ,beta -methylene-ATP consistently evoked a renal vasoconstriction (Fig. 3). Infusion of low doses of ATP induced vasodilation with a vasoconstrictor response occurring only at higher infusion doses (44). Curiously, when Vargas and co-workers (167) increased renal vascular tone with phenylephrine, low-dose ATP infusion led to a renal vasoconstriction, with vasodilation only occurring in response to infusion of high doses of ATP. The reason for these conflicting observations is unclear, but the data do suggest that the renal vascular response to infused ATP may be influenced by ambient renal vascular tone.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 3.   Renal hemodynamic response to intrarenal infusion of ATP and selected P2 agonists into the isolated perfused rat kidney under raised vascular tone conditions. Data are expressed as the %change in perfusate flow in response to increasing concentrations of agonist in the perfusate fluid. The data are selected from studies performed by Eltze and Ullrich (44).

It is interesting to note that isolated segments of human and rabbit renal arteries, preconstricted with either norepinephrine or prostaglandin F2alpha , relaxed on intraluminal exposure to ATP (137, 138). Subsequent studies revealed that the vasodilation occurred through P2Y receptor-mediated generation of nitric oxide and through the local generation of adenosine and activation of adenosine-sensitive P1 receptors (138). In a separate study, ATP-mediated vasoconstriction of rat afferent arterioles was found to be augmented during adenosine receptor blockade (85). The potential interaction between the P2 receptor system and the adenosine-sensitive P1 receptor system has not been carefully examined; however, the close association between the two receptor families and the prevalence of both receptor families in the cardiovascular system (52, 97, 118, 119, 135, 142) provide an interesting opportunity for a local integration of coregulatory roles between P1 and P2 receptor-dependent responses.

In the isolated perfused rabbit kidney, ATP infusion leads to a modest vasoconstriction (113), whereas in the dog kidney, infusion of ATP produces vasodilation by stimulating the synthesis and release of nitric oxide (101, 102). Infusion of P2Y receptor-selective agonists, such as 2-methylthio ATP, UTP, or adenosine 5'-O-(3-thiotriphosphate) (ATPgamma S) at concentrations up to 10 µM, also leads to nitric oxide-dependent vasodilation in isolated, perfused rat kidneys (28, 44), but greater concentrations lead to vasoconstriction (Fig. 3) (44). In addition, intrarenal infusion of 2-methylthio ATP or ATP into the isolated perfused rat kidney stimulates renin secretion (29), but similar infusion of the P2X agonist alpha ,beta -methylene-ATP did not effect renin secretion (29). These data suggest that luminally delivered P2Y agonists will interact with P2 receptors expressed by intrarenal endothelial cells, resulting in a nitric oxide-dependent relaxation of the intrarenal microvasculature and a decrease in renal vascular resistance. P2Y receptor-mediated vasodilation is converted to vasoconstriction during inhibition of nitric oxide synthesis, whereas P2X receptor-mediated vasoconstrictor responses are augmented (28, 44). These data suggest that intrarenal microvascular smooth muscle and endothelium express P2X and P2Y receptors; however, the results of these studies do not reveal the specific intrarenal microvascular segments that are responsible for agonist-mediated alterations in renal vascular resistance.


    ADVENTITIAL DELIVERY OF P2 AGONISTS
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

ATP released from sympathetic nerves travels through the interstitial fluid adjacent to the varicosities and binds to postsynaptic P2 receptors located on vascular smooth muscle, where it influences vascular tone (15, 21, 40, 134, 149). ATP can also be released from smooth muscle cells (127, 157), epithelial cells (60, 68, 159), and perhaps even macula densa cells (7). ATP released from such cell types would also move through the interstitial fluid space before reaching P2 receptors on vascular smooth muscle cells or other cell types to induce appropriate physiological or pathophysiological responses. In the kidney, that response may be to provide local paracrine regulation of preglomerular renal vascular resistance via activation of P2 receptors expressed by the renal microvasculature (111).

The distribution of P2X1 receptors along the renal vasculature was addressed by Chan and co-workers (25). Autoradiographic assessment of radiolabeled (3H-labeled) alpha ,beta -methylene-ATP revealed a distribution of P2 receptors along afferent arterioles and interlobular arteries, but no binding was visible along efferent arterioles. In the same study, immunohistochemical assessment for P2X1 receptors, using an antibody selective for P2X1 receptors, revealed strong positive staining along all segments of the preglomerular microvasculature, whereas no visible staining was evident along efferent arterioles or glomeruli (25). These data provide strong support for the expression of P2X1 receptors by preglomerular vascular smooth muscle cells.

Figure 4 illustrates the results of experiments conducted to determine the responsiveness of each preglomerular and postglomerular segment to ATP (85). The responsiveness of each segment was assessed at four concentrations of ATP applied in succession. These data reveal that only the arteries and arterioles comprising the preglomerular renal circulation respond to ATP administration (85). Of these segments, only the afferent arteriole exhibits a sustained vasoconstriction in response to ATP concentrations below 10 µM. Arcuate and interlobular arteries respond with a transient vasoconstriction that subsides within 2-3 min of exposure. Notably, efferent arteriolar diameter remains unchanged during ATP administration. Weihprecht et al. (171) also reported that ATP concentrations below 10 µM evoked a significant vasoconstriction of isolated rabbit afferent arterioles. These data define the functional responses of the renal microvasculature to P2 receptor activation and are in excellent agreement with the distribution of P2X1 receptors determined by immunohistochemistry and autoradiography (25).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   Average segmental diameter responses evoked by ATP applied to the adventitial surface of arcuate and interlobular arteries (A, open circle  and , respectively) and afferent and efferent arterioles (B,  and open circle , respectively). After the control period (CON), increasing concentrations of ATP from 0.1, 1.0, 10, and 100 µM were applied at 5-min intervals, as indicated by the dashed lines. Each protocol ended with a 5-min recovery period (REC), when the bath solution was returned to the control conditions. Each data point represents diameter measurements taken at 12-s intervals. The data were selected from a report by Inscho et al. (85).

As described above, the absence of highly selective agonists and antagonists creates a problem with regard to identification of the types of receptors expressed in a given tissue. Conventional pharmacological approaches to this problem include determination of rank order potency profiles using a variety of P2X and P2Y receptor agonists. This approach was used to determine the receptor subtypes possibly contributing to the afferent arteriolar response to P2 receptor activation, and the data for the sustained responses are illustrated in Fig. 5 (80). Administration of the P2X-selective agonists, alpha ,beta -methylene-ATP or beta ,gamma -methylene-ATP, yielded rapid biphasic vasoconstrictor responses consistent with the expression of P2X receptors on afferent arterioles. A typical response to alpha ,beta -methylene-ATP is illustrated in Fig. 6. The afferent arteriolar diameter response to these P2X agonists began with a rapid initial vasoconstriction that gradually declined to a smaller but sustained vasoconstriction (80). The afferent arteriolar vasoconstriction elicited by the endogenous ligand, i.e., ATP, closely paralleled the response observed after administration of the P2X agonist beta ,gamma -methylene-ATP (80, 171). Desensitization is a prominent characteristic of P2X1 and P2X3 receptors (116, 135). Accordingly, it is interesting to note the declining effectiveness of subsequent addition of higher concentrations of alpha ,beta -methylene-ATP to evoke greater vasoconstriction as would be observed in response to a single application of a high concentration. These and other data (81) suggest that the response to alpha ,beta -methylene-ATP quickly desensitized. Given that P2X1 receptors are heavily expressed along the afferent arteriole (25), it is reasonable to conclude that P2X1 receptors participate significantly in the afferent arteriolar response to ATP and P2X agonists alpha ,beta -methylene-ATP and beta ,gamma -methylene-ATP.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   Steady-state changes in microvascular diameter in response to P2 agonist administration. Data are expressed as the %decrease in afferent arteriolar diameter compared with the control diameter. Each point represents the mean vessel diameter averaged over the last 2 min of each treatment period. A: comparison of the steady-state afferent arteriolar responses to ATP and the P2X agonists, alpha ,beta -methylene-ATP (alpha -beta -ATP), and beta ,gamma -methylene-ATP(beta -gamma -ATP). B: comparison of the steady-state afferent arteriolar responses to ATP and the P2Y agonists 2-methylthio ATP, UDP, UTP, and adenosine 5'-O-(3-thiotriphosphate) (ATPgamma S). The data were selected from a report by Inscho et al. (80).



View larger version (28K):
[in this window]
[in a new window]
 
Fig. 6.   Afferent arteriolar response to alpha ,beta -methylene-ATP before and during superfusion with the dihydropyridine calcium channel blocker felodipine. Each data point represents the mean vessel diameter (in µm) measured at 12-s intervals throughout the experimental period. Arterioles were superfused with control buffer during the control and recovery periods (0-5 and 10-15 min, respectively). The arterioles were exposed to 1.0 µM alpha ,beta -methylene-ATP during the periods, as indicated by the thick horizontal bars. Calcium channel blockade was imposed with 10 µM felodipine beginning at the 15-min time point and was not interrupted. The period of calcium channel blockade by using felodipine is indicated by shaded area (right) and solid bar (middle right). The data were modified from the work of Inscho et al. (84).

Administration of the P2Y agonists 2-methylthio-ATP, ADP, UDP, UTP, or ATPgamma S in the juxtamedullary nephron preparation yielded markedly different results (Fig. 5) (78, 80). In contrast to experiments performed in the isolated perfused kidney (44), 2-methylthio ATP, ADP, and UDP induced only very slight vasoconstrictions. UTP and ATPgamma S were less potent agonists compared with ATP or the P2X agonists but, at concentrations of 10 and 100 µM, these agents elicited very large monophasic vasoconstrictions. The afferent arteriolar diameter usually closed during exposure to 100 µM concentrations of UTP and ATPgamma S, and afferent arteriolar blood flow ceased. Removal of the agonists from the bathing medium resulted in a rapid reversal of the vasoconstriction and restoration of afferent arteriolar blood flow (80). UDP had no significant effect on afferent diameter. The pattern of the afferent arteriolar vasoconstrictor response to these agents is in qualitative agreement with the results obtained in the isolated perfused kidney (44) with a few notable exceptions. In the concentration ranges used in the juxtamedullary nephron preparation, no significant vasodilatory response is observed even though the renal vasculature is under significant endogenous tone. This may reflect a difference in the concentrations tested as the vasodilatory responses in the isolated perfused kidney experiments were observed at agonist concentrations several orders of magnitude lower than were used in the juxtamedullary nephron experiments. In addition, the isolated perfused kidney experiments measure the whole kidney hemodynamic response as a reflection of the response of the entire renal vasculature to the infused agents, whereas the juxtamedullary nephron approach examines the responses of individual microvascular segments of a finite nephron population.

Taken together, these agonist response experiments suggest that at least two distinct P2 receptors are found on afferent arterioles of the rat kidney. One receptor belongs to the P2X family and responds strongly to the P2X agonists alpha ,beta -methylene-ATP or beta ,gamma -methylene-ATP. Given the existing data, it is likely that this receptor is a P2X1 receptor subtype. A second receptor probably belongs to the P2Y receptor family and is sensitive to UTP and ATPgamma S. Activation of either receptor will evoke a sustained, concentration-dependent vasoconstriction of afferent arterioles. In addition, assessment of the disparate response patterns observed between experiments performed in the isolated perfused kidney and in the juxtamedullary nephron technique suggests that P2 receptor activation may evoke more complex regional alterations in renal microvascular function and could result in zonal changes in vascular resistance and renal perfusion.


    P2 RECEPTOR-MEDIATED CALCIUM SIGNALING IN RENAL MICROVASCULAR SMOOTH MUSCLE
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

Calcium plays a major role in agonist-mediated afferent arteriolar vasoconstrictor responses, autoregulatory responses, and tubuloglomerular feedback responses (111). P2 receptor activation has also been shown to activate varied calcium signaling mechanisms involving multiple calcium influx pathways as well as mobilization of calcium from intracellular stores (111). P2X receptor stimulation activates a nonselective cation current, which can directly increase intracellular calcium concentration (39, 135). Furthermore, the net influx of cations can depolarize the plasma membrane and activate voltage-dependent calcium channels. Alternatively, P2Y receptors have been shown to be coupled to phospholipase C and generate IP3-dependent mobilization of calcium from intracellular stores (39, 135). Given the diversity of effects that may be elicited via calcium-dependent mechanisms, it is important to assess the calcium signaling pathways utilized by afferent arteriolar smooth muscle cells in responding to P2 receptor stimulation.

P2X receptor channels conduct calcium down its steep concentration gradient into the cell. Therefore, calcium influx from the extracellular medium is an important component of P2X receptor-mediated responses. Removal of calcium from the extracellular medium prevents the afferent arteriolar vasoconstriction normally evoked by alpha ,beta -methylene-ATP (84). Replenishing the extracellular calcium concentration to the physiological range also restores the alpha ,beta -methylene-ATP-mediated afferent arteriolar vasoconstriction (84). These findings demonstrate that calcium influx from the extracellular medium is an essential component in the alpha ,beta -methylene-ATP-mediated afferent arteriolar vasoconstrictor response; however, they do not identify the influx pathway involved.

Many agonists activate L-type calcium channels to stimulate vasoconstriction of afferent arterioles (111). Therefore, the role of L-type calcium channels in the afferent arteriolar response to P2 receptor activation was assessed by using different P2X and P2Y agonists. As shown in Fig. 6, P2X receptor stimulation with alpha ,beta -methylene-ATP produces a biphasic vasoconstrictor response under control conditions (78, 80, 84). Typical responses include a rapid initial vasoconstriction that reaches a maximum value within 20-30 s, followed by a partial recovery to a stable diameter significantly smaller than control. Removal of alpha ,beta -methylene-ATP from the bathing solution results in a prompt and complete recovery to the control diameter. Blockade of L-type calcium channels with felodipine (Fig. 6) or diltiazem evokes a rapid vasorelaxation, implicating L-type calcium channel activity in maintaining ambient afferent arteriolar tone. Subsequent introduction of alpha ,beta -methylene-ATP, with continued blockade of L-type calcium channels, results in attenuation of the rapid initial vasoconstriction by ~50-60% and abolition of the sustained vasoconstrictor response (84). Preliminary data reveal that stimulation of P2Y receptors with UTP evokes a more monophasic vasoconstriction that is only slightly attenuated by calcium channel blockade with diltiazem (79). Calcium channel blockade abolishes afferent arteriolar responses to low concentrations of ATP (0.1-1 µM) and significantly attenuates the responses evoked by higher concentrations of ATP (79). These data suggest that calcium influx through voltage-dependent calcium channels plays a central role in the afferent arteriolar vasoconstriction elicited by P2X receptor activation by P2X receptor-selective agonists and by low concentrations of ATP. The data also suggest that calcium channels are not the major mechanism invoked in vasoconstrictor responses evoked by P2Y receptor activation or by higher concentrations of ATP.

Subsequent studies were performed using single microvascular smooth muscle cells that were freshly isolated from rat preglomerular microvasculature. Intracellular calcium signaling in response to P2 receptor activation was examined by using the calcium-sensitive fluorescent probe fura 2. The effect of selective P2 receptor stimulation on the intracellular calcium concentration was determined under control conditions, during calcium channel blockade, and during exposure of the cells to nominally calcium-free conditions (Fig. 7). Those studies revealed that stimulation of P2Y receptors with UTP stimulated a biphasic increase in intracellular calcium concentration. The magnitude and time course of the calcium response was nearly identical compared with similarly treated cells bathed in calcium-free medium (Fig. 7) and also during calcium channel blockade with diltiazem (82). These data indicate that the renal microvascular smooth muscle cell response to UTP involves an increase in intracellular calcium that arises primarily by mobilizing calcium from intracellular stores. Preliminary data indicate that P2X receptor activation with alpha ,beta -methylene-ATP stimulates an increase in intracellular calcium concentration that is highly dependent on the influx of extracellular calcium (Fig. 7). The mechanism of the calcium influx pathway remains to be determined, but preliminary studies suggest that it is Ni2+ sensitive and can be significantly attenuated by calcium channel blockade (173). The dependency of P2X receptor activation on the influx of calcium in these cells is consistent with the role of calcium influx noted for P2X receptor-mediated afferent arteriolar vasoconstriction (79, 84, 173).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 7.   The effect of alpha ,beta -methylene-ATP (A), ATP (B), and UTP (C) on intracellular calcium concentration in freshly isolated preglomerular microvascular smooth muscle cells. Data are presented for the calcium response under control conditions with 1.8 mM calcium in the bathing medium (thick line; Control) and under nominally calcium-free conditions (thin line; Ca2+ free). The period of agonist administration was from 100 to 300 s and is indicated by the shaded bars located along the x-axes. Maximally effective concentrations of alpha ,beta -methylene-ATP (10 µM) and UTP (100 µM) were used as P2X and P2Y agonists, respectively. ATP (100 µM) was used to activate both P2X and P2Y receptors simultaneously. The data were modified from the work of Inscho et al. (82, 86, 173).

Exposure of cells to a high concentration of ATP results in an elevation of intracellular calcium concentration that depends partly on the influx of calcium through L-type calcium channels and partly on the mobilization of calcium from intracellular stores (82, 86). ATP administration elicits a biphasic increase in intracellular calcium concentration that is similar in magnitude and time course to that elicited by an equimolar concentration of UTP (Fig. 7). However, unlike the example with UTP, removal of calcium from the extracellular bathing medium reduces the magnitude of the response to ATP by ~50%. Nearly identical results are obtained when ATP is administered during calcium channel blockade (82, 86).

Conflicting results, using isolated rabbit afferent arterioles exposed to ATP or UTP, have been reported (61). ATP administration increases intracellular calcium concentration through mechanisms that appear to be entirely dependent on calcium influx. No evidence of a calcium mobilization component was observed. In addition, UTP treatment has no detectable effect on intracellular calcium concentration in similarly treated arterioles. These data suggest that there might be significant species variation in the P2 receptor population expressed by afferent arterioles of rabbit and rat kidney or that P2 receptors on these arterioles may involve alternative signal transduction pathways.

Nevertheless, these data establish that stimulation of P2 receptors on preglomerular vascular smooth muscle increases intracellular calcium concentration through multiple signal transduction pathways, possibly involving multiple P2 receptor subtypes. In rat renal microvascular smooth muscle cells, P2 receptor activation can increase calcium by stimulating calcium mobilization from intracellular stores and by stimulating calcium influx via voltage-dependent calcium influx pathways. In addition, these data lend further support to the hypothesis that afferent arteriolar smooth muscle cells express both P2X and P2Y receptor subtypes that utilize distinct calcium signaling mechanisms to influence afferent arteriolar function.


    DIADENOSINE POLYPHOSPHATES
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

Diadenosine polyphosphates are a unique group of naturally occurring nucleotide agonists that also activate P2 receptors (52, 117, 135, 142). The original descriptions of diadenosine polyphosphates in human physiology appeared in the literature in the early 1980s and described the release of diadenosine polyphosphates from human platelets (51, 100). Those early studies led investigators to suggest that diadenosine phosphates may play an important physiological role in the control of platelet aggregation. In the ensuing years, several structurally distinct and biologically active diadenosine polyphosphates have been described (142, 161, 164-166).

Diadenosine polyphosphates exist as two adenosine molecules linked by a variable number of phosphate groups. The number of phosphates is indicated by the number substituted for the X in the formula APXA. Therefore, diadenosine pentaphosphate is noted as AP5A. The number of phosphates present can have a significant impact on the biological activity of each diadenosine polyphosphate species (52, 58, 161, 164-166). The vascular response can also vary markedly depending on the specific vascular tissue being studied, the ambient vascular tone of the sample tissue or vascular bed, and the status of the endothelium (52, 142). Also important is the type of P2 receptor expressed by the tissue being studied (174).

Presently, there are several reports describing the effect of these agents on renal hemodynamics and renal function (69, 93), the renal microvasculature (58, 141, 161, 164-166), mesangial cells (96, 139, 144, 160), and cortical collecting duct cells (140). Bolus intravenous injection of AP4A, AP5A, or AP6A into the anesthetized rat resulted in a rapid and transient decline in renal blood flow that was coincident with a transient decline in heart rate, cardiac output, and mean arterial pressure (93). Assessment of renal function after intravenous injection of AP6A increased urine flow and sodium excretion, whereas AP3A or AP4A reduced urine flow and sodium excretion (69). These changes in renal function were observed without any detectable effect on glomerular filtration rate.

Intrarenal infusion of AP4A, AP5A, or AP6A into isolated perfused kidneys increases renal perfusion pressure, suggesting that these agents increase renal vascular resistance (164-166). The vasoconstriction can be observed at agonist concentrations as low as 1.0 nM (164). The renal vasoconstriction could be attenuated with the P2 receptor antagonist PPADS (164-166) and was completely blocked by combining PPADS with the P1 receptor blocker 8-cyclopentyl-1,3-dipropylxanthine (165). This observation suggests that the vasoconstrictor response is mediated partly through activation of P2X receptors and partly through activation of adenosine-sensitive P1 receptors. Large-caliber renal resistance vessels between 200 and 250 µm respond to AP4A, AP5A, and AP6A with a concentration-dependent contraction (161). The magnitude of the response was similar for each agent. The vasoconstriction evoked by AP4A could be attenuated by removal of calcium from the extracellular medium and was blocked by the calcium channel blocker nifedipine or by the nonselective P2 receptor antagonist PPADS (161).

Subsequent experiments revealed that AP3A and AP5A exert differential effects on the microvasculature of the hydronephrotic kidney (58). These agents induced transient vasoconstriction of interlobular arteries and afferent arterioles but had little effect on efferent arteriolar diameter. The vasoconstrictor response to AP3A was completely inhibited during adenosine A1 receptor blockade and was attenuated during adenosine A2 receptor blockade or with P2 receptor blockade, suggesting that P1 receptors play a major role in the response to this diadenosine polyphosphate. Vasoconstrictor responses elicited by AP5A were attenuated slightly by adenosine receptor blockade but were more sensitive to P2 receptor blockade with PPADS. These data suggest that AP5A-mediated vasoconstriction in this model is predominately mediated through P2 receptor activation (58). Therefore, it seems clear that diadenosine polyphosphates can directly alter renal microvascular diameter and resistance and that the length of the polyphosphate chain is an important consideration in determining the mechanism by which diadenosine polyphosphates influence microvascular function. The complex nature of the possible interactions between diadenosine polyphosphates and P1 and P2 receptors will certainly require considerable more study to resolve.


    WHAT PHYSIOLOGICAL ROLE DO RENAL P2 RECEPTORS FULFILL?
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

This important question is not likely to be answered in the near future. The reason for this is the wide distribution of P2 receptors throughout the kidney (3, 24, 111). P2 receptors are found on renal microvascular smooth muscle cells and endothelial cells, glomerular epithelial cells, proximal tubular cells, cultured mesangial cells, and cultured epithelial cells. Efforts are underway in several laboratories to determine the role each plays in specific tissues, but the complete picture will take time to develop.

Neural Control

One possibility is that P2 receptors serve as postsynaptic receptors that bind ATP released from sympathetic nerve terminals (3, 134, 149). Schwartz and Malik (149) have reported that low-frequency renal nerve stimulation increased renal vascular resistance through a mechanism that was insensitive to alpha -adrenergic blockade but susceptible to P2 receptor desensitization. In contrast, the renal vasoconstriction elicited by high-frequency renal nerve stimulation was sharply attenuated by alpha -adrenergic receptor blockade. Stimulation of renal nerves results in an increase in renal vascular resistance and outflow of ATP and norepinephrine in the renal venous effluent (14, 15). Blockade of P2 receptors with suramin significantly elevated the outflow of norepinephrine during renal nerve stimulation (15). These data implicate a role for P2 receptors to serve as postsynaptic receptors participating in the neural control of renal vascular resistance. They also suggest that prejunctional P2 receptors exert an inhibitory influence on sympathetic neurotransmitter release, thus buffering the influence of renal nerve activity on renal vascular resistance.

Mesangial Cells

Glomerular epithelial cells and mesangial cells also respond to P2 receptor stimulation, suggesting a possible role for P2 receptor-mediated regulation of glomerular function. The majority of the older data, as well as more current reports, are consistent with the presence of a P2Y2 receptor subtype on mesangial cells, although the presence of P2X7 receptors has also been suggested (146). Extracellular ATP and UTP induce contraction of cultured rat mesangial cells (124) in concert with an elevation of intracellular calcium concentration (62, 71, 124, 155). The increase in intracellular calcium arises from the mobilization of calcium from intracellular stores and from the influx of calcium from the extracellular medium (62, 124). Calcium channel blockade with verapamil failed to alter the magnitude or time course of ATP-mediated increases in intracellular calcium concentration, suggesting that calcium influx occurs through a mechanism independent of voltage gated L-type calcium channels (124).

ATP and UTP have also been reported to exhibit equal potency in stimulating phosphatidylcholine hydrolysis through activation of phospholipase D (131). Pretreatment with pertussis toxin significantly attenuates IP3 and 1,2-diacylglycerol (DAG) generation (129). Inhibition of protein kinase C enhances IP3 and DAG formation (129), whereas enhancement of protein kinase C activity with phorbol 12-myristate 13-acetate enhances phospholipase D activity (131). A recent report indicated that P2 receptor activation by ATP or UTP inhibited the activation of adenylate cyclase activity (145). This inhibition could only be observed during measures designed to elevate adenyl cyclase activity above baseline. No effect of these agents on baseline cAMP formation could be detected (71, 145). These data suggest that regulatory G proteins and protein kinase C are important modulatory pathways in the mesangial cell response to P2 receptor activation by ATP. The role of cAMP in the response is less clear.

Exposure of cultured mesangial cells to ATP or UTP appear to have differing effects on the magnitude and time course of changes in membrane potential (71, 124). Patch-clamp experiments reveal that ATP stimulated a transient membrane depolarization (71, 124), whereas UTP stimulated a sustained depolarization (71). Similarly, during the depolarization phase, ATP induced a transient increase in whole cell conductance, whereas UTP evoked a sustained increase in whole cell conductance (71). Reduction of the extracellular chloride concentration augmented the depolarization in response to ATP and UTP, suggesting that chloride channels participate in the depolarization response (71, 124). Interestingly, the depolarization induced by ATP can be inhibited by the nonselective P2 receptor blockers suramin and reactive blue 2, but the response to UTP is unaltered. These data suggest that responses elicited by ATP and UTP may arise from different P2 receptors.

Diadenosine polyphosphates are also known to influence mesangial cell function and thus may play a role in the control of glomerular hemodynamics. Exposure of mesangial cells to diadenosine polyphosphates stimulates membrane depolarization through activation of chloride channels and nonselective cation channels (96). Consistent with membrane depolarization and activation of nonselective cation channels, AP3A is reported to stimulate a sustained elevation in intracellular calcium concentration and mesangial cell contraction when external calcium is in the normal range but only a transient elevation in intracellular calcium concentration when external calcium is removed (139). In contrast, AP4A, AP5A, and AP6A appear to increase intracellular calcium concentration exclusively by stimulating calcium influx through voltage-gated L-type calcium channels (160). Whether these conflicting data reflect agonist-specific calcium signaling pathways or are due to experimental variation is not clear. Nevertheless, elevation of intracellular calcium is a primary response of mesangial cells challenged with diadenosine polyphosphates. Most of these responses appear to be sensitive to P2 receptor blockade with suramin or PPADS but are insensitive to adenosine A1 receptor blockade, suggesting that the responses arise through selective activation of P2 receptors (160).

The physiological or pathophysiological role of P2 receptors expressed by cultured mesangial cells remains to be determined; however, a couple of conflicting possibilities have recently been proposed. P2 receptor activation has been implicated in mesangial cell proliferation (73-75, 147, 148) and also in triggering apoptosis and necrosis (146). Exposure of mesangial cells to ATP stimulated a significant elevation in cell number, thymidine incorporation, and prostaglandin E2 production (129, 148). Similar treatment with UTP resulted in a smaller proliferative response. The mesangial cell response to ATP involves the mitogen-activated protein kinase cascade (73) and the stress-activated protein kinase cascade (74, 75). In another study, a 90-min exposure of mesangial cells to extracellular ATP caused an increase in DNA fragmentation and an increase in tumor suppressor p53 protein, which is thought to regulate apoptosis (146). Further studies implicated activation of the P2X7 receptor in the apoptotic response to ATP and confirmed the presence of P2X7 receptor-associated pore formation in the presence of ATP. Collectively, these studies suggest a possible role for mesangial P2 receptors in inflammatory cell proliferation and apoptosis (130, 147).

Vascular Smooth Muscle Cell Proliferation

The mitogenic actions of extracellular ATP have been known since 1992 (170), and these observations have been confirmed by many others using different approaches and cell systems (45, 45-47, 65, 103, 170). ATP has been shown to stimulate DNA synthesis (45-47, 170) and protein synthesis (45, 47) in vascular smooth muscle cells cultured from rat aorta and vena cava and human subcutaneous arteries and veins. Stimulation of the proliferative response appears to involve activation of P2Y receptors and is reported to occur in response to a wide variety of nucleotide agonists, including ATP, UTP, UDP, ADP, and AP4A (45-47, 65, 103). P2Y receptor activation initiates a broad series of intracellular events, culminating in cell growth and proliferation. Included in the signaling pathways appear to be crucial steps for tyrosine kinase (45, 46) and mitogen-activated protein kinase (45, 65). Similar studies examining the potential role of extracellular nucleotides to stimulate, or regulate, preglomerular vascular smooth muscle cell growth have not been performed. Nevertheless, the implication is intriguing that locally released adenine nucleotides could participate in renal microvascular remodeling, under physiological or pathophysiological conditions.

Autoregulatory Control

The kidney has the unique ability to regulate renal blood flow and glomerular filtration rate at near-constant levels over a wide range of arterial pressures. The phenomenon of renal blood flow autoregulation has been recognized for many years; however, our understanding of the specific mechanisms by which it occurs remains incomplete. It is known that autoregulatory alterations in renal vascular resistance involve sustained adjustments in preglomerular resistance and that most of the resistance change occurs at the afferent arteriole. Interestingly, ATP-mediated renal vasoconstriction occurs exclusively at the preglomerular microvasculature, with afferent arterioles exhibiting sustained responses (Fig. 4) (85). Autoregulatory adjustments in afferent arteriolar diameter are sensitive to calcium channel blockade (Fig. 6) as are ATP-mediated afferent arteriolar responses (84). Therefore, experiments were performed to test the postulate that afferent arteriolar P2 receptors play an important role in mediating renal autoregulatory responses.

Studies were conducted in vitro using the juxtamedullary nephron technique in the isolated rat kidney and examined the effect of P2 receptor inactivation on autoregulatory behavior (81). P2 receptor inactivation was accomplished by imposing P2 receptor desensitization or saturation and by pharmacological blockade. The results of those studies revealed that inactivation of P2 receptors by receptor desensitization abolished pressure-mediated autoregulatory reductions in afferent arteriolar diameter (81). An alternative approach to inactivation of the P2 receptor influence on autoregulatory responses was implemented by clamping the extracellular ATP concentration by adding high concentrations of ATP to the exogenous medium. Under these conditions, the influence of endogenously released ATP would be overwhelmed by the exogenous ATP present in the bathing medium. Under ATP-clamp conditions, pressure-mediated afferent arteriolar autoregulatory responses were completely blocked (81). Interestingly, this inhibition of autoregulatory behavior was obtained despite the fact that afferent arteriolar responsiveness to other non-P2 vasoconstrictor agonists such as KCl, angiotensin II, or norepinephrine was well preserved (81).

In another series of experiments, we examined the effect of pharmacological inactivation of P2 receptors on autoregulatory behavior (Fig. 8). Autoregulatory responsiveness was examined before and during exposure of the vasculature to the nonselective P2 receptor antagonists PPADS or suramin (81). Under control conditions, elevation of renal perfusion pressure in 30-mmHg increments from 100 to 130 and 160 mmHg resulted in appropriate pressure-mediated reductions in afferent arteriolar diameter. However, during blockade of P2 receptors with PPADS, the pressure-mediated vasoconstrictor responses were abolished and afferent arteriolar diameter remained unchanged. Suramin administration consistently increased baseline afferent arteriolar diameter. Similar to the effect of PPADS on autoregulatory behavior, P2 receptor blockade with suramin resulted in a marked attenuation of the pressure-mediated vasoconstrictor responses (81). Therefore, each experimental manipulation designed to selectively inactivate afferent arteriolar P2 receptors simultaneously blocked normal afferent arteriolar autoregulatory behavior. The confirmation that afferent arterioles retained normal responsiveness to other vasoconstrictor stimuli supports the contention that the functional integrity of the contractile apparatus remained intact during P2 receptor inactivation but that the ability of the arteriole to respond to a pressure stimulus was impaired. These fundamental observations are consistent with selective inhibition of the autoregulatory response by P2 receptor inactivation and strongly implicate P2 receptor activation as an essential step in pressure-mediated autoregulatory adjustments in afferent arteriolar diameter. These data also suggest that ATP may be constitutively released, which underscores the necessity to quantify how much ATP is being released into the interstitial fluid under basal and stimulated conditions.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of P2 receptor blockade with pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS) or suramin on the afferent arteriolar response to acute increases in renal perfusion pressure. The afferent arteriolar diameter response to an increase in perfusion pressure is shown during the control period () and during exposure to 50 µM PPADS (open circle ) or suramin (gray circles). Mean diameter of afferent arterioles is given in µm. The time course of the response during PPADS or suramin administration has been overlaid on the control response for comparison. The data were modified from the work of Inscho et al. (81).

Complimentary studies were performed in vivo, in the dog kidney, where the extracellular ATP concentration was clamped at a high level while the effect of alterations in renal arterial pressure on renal blood flow and glomerular filtration rate was examined (101). In these experiments (Fig. 9), the kidney was pretreated with the nitric oxide synthase inhibitor nitro-L-arginine to eliminate the vasodilation that accompanies infusion of ATP into the renal artery of the dog (102). As shown in Fig. 9, renal blood flow was well autoregulated over renal arterial pressures ranging from ~75 to 150 mmHg under control conditions (101). During the ATP-clamp period, renal blood flow declined proportionally with each decrement in renal perfusion pressure (Fig. 9). Control experiments confirmed that impairment of autoregulatory responsiveness during the ATP clamp could not be attributed to a nonspecific ATP-dependent elevation in renal vascular resistance, because a similar reduction in autoregulatory efficiency was not observed when renal vascular resistance was increased to a similar extent with norepinephrine. Therefore, selective inhibition of a P2 receptor-dependent signaling pathway appears to lead to simultaneous impairment of autoregulatory behavior. Taken together, the in vitro and in vivo evidence obtained from two different species, under different experimental conditions, strongly support the hypothesis that renal microvascular P2 receptors play a central role in mediating pressure-dependent autoregulatory adjustments in afferent arteriolar diameter.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 9.   Effect of ATP and norepinephrine infusion on renal blood flow to changes in renal arterial pressure in the dog kidney. Dogs were pretreated with nitro-L-arginine (NLA) to inhibit endogenous nitric oxide synthase, and autoregulatory capability was assessed in response to step reductions in renal arterial pressure. , Control responses in NLA-treated dogs; , the response during intrarenal infusion of ATP. To control for the effects of ATP-mediated renal vasoconstriction on the autoregulatory profile, parallel studies were performed during the intrarenal infusion of norepinephrine (black-triangle). Norepinephrine was infused to induce a similar decrease in renal blood flow as observed during ATP infusion. The data were modified from the work of Majid et al. (101).

Tubuloglomerular Feedback

Autoregulation of renal blood flow and glomerular filtration rate occurs through the combined influences of myogenic- and tubuloglomerular feedback (TGF)-dependent mechanisms. Regulation of preglomerular resistance through TGF-dependent influences involves alterations in afferent arteriolar diameter in response to signals transmitted from the macula densa. Although there is general agreement that the TGF mechanism is an important contributor to the overall regulation of renal hemodynamics, identification of the "signal" that links macula densa function with alterations in preglomerular resistance has not been accomplished.

Recent data assessing the effect of P2 receptor inactivation on autoregulation support the hypothesis that extracellular ATP activates afferent arteriolar P2 receptors to simulate autoregulatory adjustments in preglomerular resistance. If these changes in afferent diameter occur as a consequence of TGF-mediated signals, then pressure-mediated stimulation of afferent arteriolar vasoconstriction should occur in response to an increase in the concentration of ATP in the interstitial fluid of the renal cortex. Nishiyama et al. (114) performed experiments in the dog, using the dialysis tubing technique of Siragy and Linden (152), in an attempt to address this hypothesis. Experiments were designed to measure changes in renal cortical interstitial ATP concentration in response to alterations in renal arterial pressure. The concentration of ATP in the interstitial fluid was estimated by measuring the ATP concentration equilibrium in dialysate collected from microdialysis tubing implanted in the renal cortex. The results of those studies revealed that the concentration of ATP measured in the dialysate, equilibrated with renal cortical interstitial fluid, varied in direct proportion with renal arterial pressure (Fig. 10, left). Additionally, the change in interstitial ATP concentration was also significantly correlated with pressure-mediated changes in renal vascular resistance (114). Interestingly, whereas changes in interstitial ATP concentration correlated directly with changes in renal arterial pressure, no relationship was observed between renal arterial pressure and interstitial adenosine concentration (114). These data are consistent with the hypothesis that acute elevations in renal arterial pressure stimulate an elevation in renal interstitial ATP concentration leading to an elevation in renal vascular resistance. The data do not support a significant role for interstitial adenosine in mediating autoregulatory adjustments in renal vascular resistance.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 10.   Left: relationship between renal arterial pressure and renal vascular resistance (RVR; top) and interstitial ATP concentration (bottom). Interstitial ATP concentration was measured in dialysate fluid equilibrated with renal cortical interstitial fluid. Right: effect of manipulating distal tubular fluid flow on interstitial ATP concentration. ATP concentration was measured under control conditions (solid bar), during accelerated distal tubular fluid flow induced by acetazolamide administration (open bars), and during inhibition of tubuloglomerular feedback with furosemide (hatched bars). The data were modified from the work of Nishiyama et al. (114).

In similar experiments, Nishiyama et al. (114) assessed the effect of manipulating the TGF mechanism on interstitial ATP concentration. The TGF mechanism was stimulated by administering acetazolamide to increase distal tubular solute delivery. Alternatively, TGF activity was blocked by administering furosemide (Fig. 10, right). As predicted by the TGF hypothesis, increasing TGF signaling by increasing distal tubular solute delivery resulted in a significant elevation of the renal interstitial ATP concentration (114). Subsequent inhibition of TGF signals with furosemide evoked a rapid decline in interstitial ATP concentration to values below those obtained under control conditions.

More recent preliminary data from Bell et al. (7) suggest the possible detection of ATP release from the basolateral aspect of macula densa. This release was measured by using a novel biosensor designed to detect P2 receptor activation after exposure of macula densa cells to an osmotic stimulus (7). When the biosensor, expressing P2 receptors, was placed adjacent to the basolateral surface, detectable membrane currents were obtained. In contrast, similar responses were not detected when the biosensor was moved a considerable distance away from the macula densa cells. Although these data are highly preliminary, they do mark a clever and novel approach to determining whether macula densa cells are capable of controlled release of ATP into the pericellular space in response to a stimulus. These correlative data are consistent with the hypothesis that activation of TGF signals from the macula densa stimulates ATP release into the renal cortical interstitial fluid, where it activates P2 receptors on afferent arterioles to induce vasoconstriction.

Using an in vivo micropuncture approach, Mitchell and Navar (106) demonstrated that infusion of ATP, or the P2X agonist beta ,gamma -methylene-ATP, into the peritubular capillary circulation attenuated TGF responsiveness (106). In those studies, an ATP clamp was imposed by infusing high concentrations of these P2 agonists into the peritubular circulation while the TGF-mediated stop-flow pressure response to increases in late proximal tubule perfusion rate was being measured. Under control conditions, increasing late proximal perfusion rate from 0 to 40 nl/min caused a marked reduction in stop-flow pressure (Fig. 11), consistent with TGF-mediated afferent arteriolar vasoconstriction. However, during simultaneous peritubular capillary infusion of P2 agonists, the stop-flow pressure response to an identical increase in proximal perfusion rate was markedly attenuated (Fig. 11, left). Similar responses could not be obtained during administration of adenosine (Fig. 11, right) or the nonselective adenosine receptor blocker 1,3 dipropyl-8-p-sulfophenylxanthine (106). These data suggest that P2 rather than P1 receptors are responsible for the noted reduction in stop-flow pressure during P2 agonist infusion and support the hypothesis that P2 receptor activation is a central mechanism involved in TGF-mediated autoregulatory adjustments in afferent arteriolar resistance.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 11.   The effects of peritubular capillary infusions of 1 mM ATP (A, open circle ), beta ,gamma -methylene-ATP (A, gray circles), and adenosine (B, gray circles) on the tubuloglomerular feedback-mediated stop-flow pressure response induced by increasing late proximal perfusion rate from 0 to 40 nl/min. Stop-flow pressure responses were measured under control conditions () while P1 and P2 receptor stimulation was clamped by peritubular infusion of P2 and P1 agonists. The data were modified from the work of Mitchell et al. (106).


    FINAL PERSPECTIVES
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

More questions than answers are being generated as investigators continue to probe the involvement of P2 receptors in various physiological and/or pathophysiological conditions. In the course of past investigations, much has been learned about the pharmacology of P2 receptor agonists and antagonists and about the varied nature of P2 receptors that mediate biological responses. These studies have given rise to new ideas regarding the possible roles these receptors might play in regulating aspects of organ and tissue function. However, from a physiological perspective, many important questions remain before a serious case can be made that P2 receptors are integrally involved in regulating organ or tissue function. The postulate that P2 receptors are involved in the physiological regulation of renal microvascular function and autoregulatory behavior is comparatively new and not firmly established. Nevertheless, the data presently available provide compelling support for the involvement of P2 receptors in regulating renal microvascular function. The nature of the nucleotide signal remains to be identified. Is it an adenine nucleotide or nucleoside, or could it be one of several diadenosine polyphosphate compounds? What role is played by pyrimidine nucleotides like UTP and UDP? What role, if any, does adenosine play in these responses? What is the source of the extracellular messenger, and what is the mechanism for its release to the interstitial fluid? What role, if any, does the macula densa play in the P2 receptor-dependent regulation of afferent arteriolar diameter? What receptor subtype or subtypes are involved in the microvascular and/or glomerular response to extracellular nucleotides. Are the functional receptors on the microvasculature in the monomeric form, or are they perhaps expressed as heteromeric receptor complexes that might confer unique, tissue-specific properties for the selective regulation of tissue function? With continued effort, answers to these and other questions will be obtained. Progress in this field awaits the development of new and better receptor agonists and antagonists with which to selectively probe receptor function and the intracellular signaling pathways involved. Adoption of new molecular approaches promises to provide a greater understanding of the pharmacology of these receptors and lead to the development of engineered animal models with which to assess the roles of discreet receptor subtypes. Regardless of the limitations presently faced, the challenges that lie ahead are not insurmountable. Persistent efforts will undoubtedly yield new insights into the role that P2 receptors play in regulating renal tubular and microvascular function. With these new insights, the renal P2 receptor system may emerge as a major new mechanism responsible for the physiological regulation of renal function.


    ACKNOWLEDGEMENTS

The author thanks Anthony K. Cook, Bao Thang Pham, Elizabeth A. LeBlanc, Alan C. Schroeder, and Steven M. White for excellent technical assistance. The author also thanks Drs. John D. Imig and Robert A. Johnson for critical review of the manuscript.


    FOOTNOTES

The author has been supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants R29-DK-44628 and RO1-DK-44628, Grants-in-Aid from the Louisiana affiliate of the American Heart Association, and an Established Investigator Award from the National American Heart Association. Earlier work was supported by the National Kidney Foundation. The studies on the renal microvascular response to P2 receptor stimulation were performed by the author while in the Department of Physiology at the Tulane University School of Medicine.

Address for reprint requests and other correspondence: E. W. Inscho, Dept. of Physiology, Medical College of Georgia, 1120 15th St., Augusta, GA 30912-3000 (E-mail: einscho{at}mail.mcg.edu).


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
PURINOCEPTOR CLASSIFICATION
P2 RECEPTOR AGONISTS AND...
P2 RECEPTOR DISTRIBUTION WITHIN...
RENAL VASCULAR RESPONSE TO...
ADVENTITIAL DELIVERY OF P2...
P2 RECEPTOR-MEDIATED CALCIUM...
DIADENOSINE POLYPHOSPHATES
WHAT PHYSIOLOGICAL ROLE DO...
FINAL PERSPECTIVES
REFERENCES

1.   Abbracchio, MP, and Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64: 445-475, 1994[ISI][Medline].

2.   Aki, Y, Tomohiro A, Nishiyama A, Kiyomoto K, Kimura S, and Abe Y. Effects of KW-3902, a selective and potent adenosine A1 receptor antagonist, on renal hemodynamics and urine formation in anesthetized dogs. Pharmacology 55: 193-201, 1997[ISI][Medline].

3.   Bailey, MA, Hillman KA, and Unwin RJ. P2 receptors in the kidney. J Auton Nerv Syst 81: 264-270, 2000[ISI][Medline].

4.   Barnard, EA, Simon J, and Webb TE. Nucleotide receptors in the nervous system---an abundant component using diverse transduction mechanisms. Mol Neurobiol 15: 103-129, 1997[ISI][Medline].

5.   Barrett, RJ, and Droppleman DA. Interactions of adenosine A1 receptor-mediated renal vasoconstriction with endogenous nitric oxide and ANG II. Am J Physiol Renal Fluid Electrolyte Physiol 265: F651-F659, 1993[Abstract/Free Full Text].

6.   Beigi, R, Kobatake E, Aizawa M, and Dubyak GR. Detection of local ATP release from activated platelets using cell surface-attached firefly luciferase. Am J Physiol Cell Physiol 276: C267-C278, 1999[Abstract/Free Full Text].

7.   Bell, PD, Lapointe JY, Sabirov R, Hayashi S, and Okada Y. Maxi-chloride channel in macula densa cells: possible pathway for ATP release (Abstract). FASEB J 14: A134, 2000.

8.   Bellamkonda, KK, Chou CL, and Knepper MA. Extracellular nucleotide receptor inhibits AVP-stimulated water permeability in inner medullary collecting duct. Am J Physiol Renal Fluid Electrolyte Physiol 269: F863-F869, 1995[Abstract/Free Full Text].

9.   Bidet, M, De Renzis G, Martial S, Rubera I, Tauc M, and Poujeol P. Extracellular ATP increases [Ca2+]i in distal tubule cells. I. Evidence for a P2Y2 purinoceptor. Am J Physiol Renal Physiol 279: F92-F101, 2000[Abstract/Free Full Text].

10.   Bo, X, and Burnstock G. Heterogeneous distribution of [3H]alpha ,beta -methylene ATP binding sites in blood vessels. J Vasc Res 30: 87-101, 1993[ISI][Medline].

11.   Bo, X, Schoepfer R, and Burnstock G. Molecular cloning and characterization of a novel ATP P2X receptor subtype from embryonic chick skeletal muscle. J Biol Chem 275: 14401-14407, 2000[Abstract/Free Full Text].

12.   Bodin, P, Bailey D, and Burnstock G. Increased flow-induced ATP release from isolated vascular endothelial cells but not smooth muscle cells. Br J Pharmacol 103: 1203-1205, 1991[Abstract].

13.   Bodin, P, and Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res 47: 351-354, 1998[ISI][Medline].

14.   Bohmann, C, Rump LC, Schaible U, and Von Kügelgen I. alpha -Adrenoceptor modulation of norepinephrine and ATP release in isolated kidneys of spontaneously hypertensive rats. Hypertension 25: 1224-1231, 1995[Abstract/Free Full Text].

15.   Bohmann, C, Von Kügelgen I, and Rump LC. P2-receptor modulation of noradrenergic neurotransmission in rat kidney. Br J Pharmacol 121: 1255-1262, 1997[Abstract].

16.   Brändle, U, Spielmanns P, Osteroth R, Sim J, Surprenant A, Buell G, Ruppersberg JP, Plinkert PK, Zenner HP, and Glowatzki E. Desensitization of the P2X2 receptor controlled by alternative splicing. FEBS Lett 404: 294-298, 1997[ISI][Medline].

17.   Briner, VA, and Kern F. ATP stimulates Ca2+ mobilization by a nucleotide receptor in glomerular endothelial cells. Am J Physiol Renal Fluid Electrolyte Physiol 266: F210-F217, 1994[Abstract/Free Full Text].

18.   Burnstock, G. Purinergic nerves. Pharmacol. Rev 24: 509-581, 1972[ISI][Medline].

19.   Burnstock, G. A basis for distinguishing two types of purinergic receptor. In: Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach, edited by Bolis L, and Straub RCO. New York: Raven, 1978, p. 107-118.

20.   Burnstock, G. Purinoceptors: ontogeny and phylogeny. Drug Dev Res 39: 204-242, 1996[ISI].

21.   Burnstock, G. Purinergic signalling: therapeutic potential. Drug Dev Res 45: 86-92, 1998[ISI].

22.   Carmines, PK, and Inscho EW. Renal arteriolar angiotensin responses during varied adenosine receptor activation. Hypertension 23: I-114-I-119, 1994.

23.   Cejka, JC, Bidet M, Tauc M, and Poujeol P. Nucleotides mobilize intracellular calcium stores of renal proximal cells in primary culture: existence of a suramin-sensitive mechanism. Biochim Biophys Acta 1176: 7-12, 1993[ISI][Medline].

24.   Cha, SH, Sekine T, and Endou H. P2 purinoceptor localization along rat nephron and evidence suggesting existence of subtypes P2Y1 and P2Y2. Am J Physiol Renal Physiol 274: F1006-F1014, 1998[Abstract/Free Full Text].

25.   Chan, CM, Unwin RJ, Bardini M, Oglesby IB, Ford APDW, Townsend-Nicholson A, and Burnstock G. Localization of the P2X1 purinoceptors by autoradiography and immunohistochemistry in the rat kidney. Am J Physiol Renal Physiol 274: F799-F804, 1998[Abstract/Free Full Text].

26.   Chan, CM, Unwin RJ, and Burnstock G. Potential functional roles of extracellular ATP in kidney and urinary tract. Exp Nephrol 6: 200-207, 1998[ISI][Medline].

27.   Churchill, PC, and Bidani A. Renal effects of selective adenosine receptor agonists in anesthetized rats. Am J Physiol Renal Fluid Electrolyte Physiol 252: F299-F303, 1987[Abstract/Free Full Text].

28.   Churchill, PC, and Ellis VR. Pharmacological characterization of the renovascular P2 purinergic receptors. J Pharmacol Exp Ther 265: 334-338, 1993[Abstract].

29.   Churchill, PC, and Ellis VR. Purinergic P2Y receptors stimulate renin secretion by rat renal cortical slices. J Pharmacol Exp Ther 266: 160-163, 1993[Abstract].

30.   Communi, D, and Boeynaems JM. Receptors responsive to extracellular pyrimidine nucleotides. Trends Pharmacol Sci 18: 83-86, 1997[ISI][Medline].

31.   Communi, D, Govaerts C, Parmentier M, and Boeynaems JM. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol Chem 272: 31969-31973, 1997[Abstract/Free Full Text].

32.   Communi, D, Janssens R, Suarez-Huerta N, Robaye B, and Boeynaems JM. Advances in signalling by extracellular nucleotides: the role and transduction mechanisms of P2Y receptors. Cell Signal 12: 351-360, 2000[ISI][Medline].

33.   Conigrave, AD, and Jiang L. Ca2+-mobilizing receptors for ATP and UTP. Cell Calcium 17: 111-119, 1995[ISI][Medline].

34.   Cressman, VL, Lazarowski E, Homolya L, Boucher RC, Koller BH, and Grubb BR. Effect of loss of P2Y2 receptor gene expression on nucleotide regulation of murine epithelial Cl- transport. J Biol Chem 274: 26461-26468, 1999[Abstract/Free Full Text].

35.   Dietrich, HH, Ellsworth ML, Sprague RS, and Dacey RG, Jr. Red blood cell regulation of microvascular tone through adenosine triphosphate. Am J Physiol Heart Circ Physiol 278: H1294-H1298, 2000[Abstract/Free Full Text].

36.   Dietrich, MS, Endlich K, Parekh N, and Steinhausen M. Interaction between adenosine and angiotensin II in renal microcirculation. Microvasc Res 41: 275-288, 1991[ISI][Medline].

37.   Dinour, D, Agmon Y, and Brezis M. Adenosine: an emerging role in the control of renal medullary oxygenation. Exp Nephrol 1: 152-157, 1993[ISI][Medline].

38.   Dinour, D, and Brezis M. Effects of adenosine on intrarenal oxygenation. Am J Physiol Renal Fluid Electrolyte Physiol 261: F787-F791, 1991[Abstract/Free Full Text].

39.   Dubyak, GR, and El-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol Cell Physiol 265: C577-C606, 1993[Abstract/Free Full Text].

40.   Dunn, WR, Brock JA, and Hardy TA. Electrochemical and electrophysiological characterization of neurotransmitter release from sympathetic nerves supplying rat mesenteric arteries. Br J Pharmacol 128: 174-180, 1999[Abstract/Free Full Text].

41.   Edgecombe, M, Craddock HS, Smith DC, McLennan AG, and Fisher MJ. Diadenosine polyphosphate-stimulated gluconeogenesis in isolated rat proximal tubules. Biochem J 323: 451-456, 1997[ISI][Medline].

42.   El-Moatassim, C, Dornand J, and Mani JC. Extracellular ATP and cell signalling. Biochim Biophys Acta 1134: 31-45, 1992[ISI][Medline].

43.   Ellsworth, ML, Forrester T, Ellis CG, and Dietrich HH. The erythrocyte as a regulator of vascular tone. Am J Physiol Heart Circ Physiol 269: H2155-H2161, 1995[Abstract/Free Full Text].

44.   Eltze, M, and Ullrich B. Characterization of vascular P2 purinoceptors in the rat isolated perfused kidney. Pflügers Arch 306: 139-152, 1996.

45.   Erlinge, D. Extracellular ATP: A growth factor for vascular smooth muscle cells. Gen Pharmacol 31: 1-8, 1998[Medline].

46.   Erlinge, D, Heilig M, and Edvinsson L. Tyrphostin inhibition of ATP-stimulated DNA synthesis, cell proliferation and Fos-protein expression in vascular smooth muscle cells. Br J Pharmacol 118: 1028-1034, 1996[Abstract].

47.   Erlinge, D, Yoo H, Edvinsson L, Reis DJ, and Wahlestedt C. Mitogenic effects of ATP on vascular smooth muscle cells vs. other growth factors and sympathetic cotransmitters. Am J Physiol Heart Circ Physiol 265: H1089-H1097, 1993[Abstract/Free Full Text].

48.   Evans, RJ, Surprenant A, and North RA. P2X receptors: cloned and expressed. In: The P2 Nucleotide Receptors, edited by Turner JT, Weisman GA, and Fedan JS.. Totowa, NJ: Humana, 1998, p. 43-61.

49.   Fernández, O, Wangensteen R, Osuna A, and Vargas F. Renal vascular reactivity to P2-purinoceptor activation in spontaneously hypertensive rats. Pharmacology 60: 47-50, 2000[ISI][Medline].

50.   Flezar, M, and Heisler S. P2-purinergic receptors in human breast tumor cells: coupling of intracellular calcium signaling to anion secretion. J Pharmacol Exp Ther 263: 1499-1510, 1993.

51.  Flodgaard H and Klenow H. Abundant amounts of diadenosine 5',5'''-P1,P4-tetraphosphate are present and releasable, but metabolically inactive, in human platelets. Biochem J 737-742, 1982.

52.   Flores, NA, Stavrou BM, and Sheridan DJ. The effects of diadenosine polyphosphates on the cardiovascular system. Cardiovasc Res 42: 15-26, 1999[ISI][Medline].

53.   Forrester, T. An estimate of ATP release into the venous effluent from exercising human forearm muscle. J Physiol (Lond) 224: 611-628, 1972[ISI][Medline].

54.   Forrester, T, and Lind AR. Identification of ATP in human plasma and the concentration in the venous effluent of forearm muscles before, during and after sustained contractions. J Physiol (Lond) 204: 347-364, 1969[ISI][Medline].

55.   Fredholm, BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, and Williams M. Nomenclature and classification of purinoceptors. Pharmacol Rev 46: 143-156, 1994[ISI][Medline].

56.   Fredholm, BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, Schwabe U, and Williams M. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci 18: 79-82, 1997[ISI][Medline].

57.   Fredholm, BB, Arslan C, Kull B, Kontny E, and Svenningsson P. Adenosine (P1) receptor signalling. Drug Dev Res 39: 262-268, 1996[ISI].

58.   Gabriëls, G, Endlich K, Rahn KH, Schlatter E, and Steinhausen M. In vivo effects of diadenosine polyphosphates on rat renal microcirculation. Kidney Int 57: 2476-2484, 2000[ISI][Medline].

59.   Gloy, J, Greger R, Schollmeyer P, Huber M, and Pavenstädt H. Influence of cell culture conditions and passage number on the response of membrane voltage to ATP and angiotensin II in rat mesangial cells. Renal Physiol Biochem 17: 62-72, 1994[ISI][Medline].

60.   Grygorczyk, R, and Hanrahan JW. CFTR-independent ATP release from epithelial cells triggered by mechanical stimuli. Am J Physiol Cell Physiol 272: C1058-C1066, 1997[Abstract/Free Full Text].

61.   Gutiérrez, AM, Kornfeld M, and Persson AEG Calcium response to adenosine and ATP in rabbit afferent arterioles. Acta Physiol Scand 166: 175-181, 1999[ISI][Medline].

62.   Gutierrez, AM, Lou XF, Persson AEG, and Ring A. Ca2+ response of rat mesangial cells to ATP analogues. Eur J Pharmacol 369: 107-112, 1999[ISI][Medline].

63.   Harada, H, Chan CM, Loesch A, Unwin R, and Burnstock G. Induction of proliferation and apoptotic cell death via P2Y and P2X receptors, respectively, in rat glomerular mesangial cells. Kidney Int 57: 949-958, 2000[ISI][Medline].

64.   Harden, TK, Boyer JL, and Nicholas RA. P2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 35: 541-579, 1995[ISI][Medline].

65.   Harper, S, Webb TE, Charlton SJ, Ng LL, and Boarder MR. Evidence that P2Y4 nucleotide receptors are involved in the regulation of rat aortic smooth muscle cells by UTP and ATP. Br J Pharmacol 124: 703-710, 1998[Abstract].

66.   Harris, RC. The macula densa: recent developments. J Hypertens 14: 815-822, 1996[ISI][Medline].

67.   Haynes, JM. A2A adenosine receptor mediated potassium channel activation in rat epididymal smooth muscle. Br J Pharmacol 130: 685-691, 2000[Abstract/Free Full Text].

68.   Hazama, A, Shimizu T, Ando-Akatsuka Y, Hayashi S, Tanaka S, Maeno E, and Okada Y. Swelling-induced, CFTR-independent ATP release from a human epithelial cell line---lack of correlation with volume-sensitive Cl- channels. J Gen Physiol 114: 525-533, 1999[Abstract/Free Full Text].

69.   Hohage, H, Reinhardt C, Borucki U, Enck G, Schlüter H, Schlatter E, and Zidek W. Effects of diadenosine polyphosphates on renal function and blood pressure in anesthetized Wistar rats. J Am Soc Nephrol 7: 1216-1222, 1996[Abstract].

70.   Homolya, L, Watt WC, Lazarowski ER, Koller BH, and Boucher RC. Nucleotide-regulated calcium signaling in lung fibroblasts and epithelial cells from normal and P2Y2 receptor (-/-) mice. J Biol Chem 274: 26454-26460, 1999[Abstract/Free Full Text].

71.   Huber-Lang, M, Fischer KG, Gloy J, Schollmeyer P, Kramer-Guth A, Greger R, and Pavenstadt H. UTP and ATP induce different membrane voltage responses in rat mesangial cells. Am J Physiol Renal Physiol 272: F704-F711, 1997[Abstract/Free Full Text].

72.   Huwiler, A, Briner VA, Fabbro D, and Pfeilschifter J. Feedback regulation of extracellular ATP-stimulated phosphoinositide hydrolysis by protein kinase C-alpha in bovine glomerular endothelial cells. Kidney Int 52: 329-337, 1997[ISI][Medline].

73.   Huwiler, A, and Pfeilschifter J. Stimulation by extracellular ATP and UTP of the mitogen-activated protein kinase cascade and proliferation of rat renal mesangial cells. Br J Pharmacol 113: 1455-1463, 1994[Abstract].

74.   Huwiler, A, Van Rossum G, Wartmann M, and Pfeilschifter J. Stimulation by extracellular ATP and UTP of the stress-activated protein kinase cascade in rat renal mesangial cells. Br J Pharmacol 120: 807-812, 1997[Abstract].

75.   Huwiler, A, Wartmann M, Van den Bosch H, and Pfeilschifter J. Extracellular nucleotides activate the p38-stress-activated protein kinase cascade in glomerular mesangial cells. Br J Pharmacol 129: 612-618, 2000[Abstract/Free Full Text].

76.   Inscho, EW. Purinoceptor-mediated regulation of the renal microvasculature. J Auton Pharmacol 16: 385-388, 1996[ISI][Medline].

77.   Inscho, EW, Belott TP, Mason MJ, Smith JB, and Navar LG. Extracellular ATP increases cytosolic calcium in cultured renal arterial smooth muscle cells. Clin Exp Pharmacol Physiol 23: 503-507, 1996[ISI][Medline].

78.   Inscho, EW, Carmines PK, and Navar LG. Juxtamedullary afferent arteriolar responses to P1 and P2 purinergic stimulation. Hypertension 17: 1033-1037, 1991[Abstract].

79.   Inscho, EW, and Cook AK. Effect of calcium channel blockade on UTP-mediated afferent arteriolar vasoconstriction (Abstract). FASEB J 14: A718, 1999.

80.   Inscho, EW, Cook AK, Mui V, and Miller J. Direct assessment of renal microvascular responses to P2-purinoceptor agonists. Am J Physiol Renal Physiol 274: F718-F727, 1998[Abstract/Free Full Text].

81.   Inscho, EW, Cook AK, and Navar LG. Pressure-mediated vasoconstriction of juxtamedullary afferent arterioles involves P2-purinoceptor activation. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1077-F1085, 1996[Abstract/Free Full Text].

82.   Inscho, EW, LeBlanc EA, Pham BT, White SM, and Imig JD. Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension 33: 195-200, 1999[Abstract/Free Full Text].

83.   Inscho, EW, Mitchell KD, and Navar LG. Extracellular ATP in the regulation of renal microvascular function. FASEB J 8: 319-328, 1994[Abstract/Free Full Text].

84.   Inscho, EW, Ohishi K, Cook AK, Belott TP, and Navar LG. Calcium activation mechanisms in the renal microvascular response to extracellular ATP. Am J Physiol Renal Fluid Electrolyte Physiol 268: F876-F884, 1995[Abstract/Free Full Text].

85.   Inscho, EW, Ohishi K, and Navar LG. Effects of ATP on pre- and postglomerular juxtamedullary microvasculature. Am J Physiol Renal Fluid Electrolyte Physiol 263: F886-F893, 1992[Abstract/Free Full Text].

86.   Inscho, EW, Schroeder AC, Deichmann PC, and Imig JD. ATP-mediated Ca2+ signaling in preglomerular smooth muscle cells. Am J Physiol Renal Physiol 276: F450-F456, 1999[Abstract/Free Full Text].

87.   Ishikawa, S, Higashiyama M, Kusaka I, Saito T, Nagasaka S, and Fukuda S. Extracellular ATP promotes cellular growth of renal inner medullary collecting duct cells mediated via P2u receptors. Nephron 76: 208-214, 1997[ISI][Medline].

88.   Jacobson, KA. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19: 184-191, 1998[ISI][Medline].

89.   Jacobson, KA, Moro S, Kim YC, and Li AH. A3 adenosine receptors: protective vs. damaging effects identified using novel agonists and antagonists. Drug Dev Res 45: 113-124, 1998[ISI].

90.   Jin, WW, and Hopfer U. Purinergic-mediated inhibition of Na+-K+-ATPase in proximal tubule cells: elevated cytosolic Ca2+ is not required. Am J Physiol Cell Physiol 272: C1169-C1177, 1997[Abstract/Free Full Text].

91.   Joyner, WL, Mohama RE, Myers TO, and Gilmore JP. The selective response to adenosine of renal microvessels from hamster explants. Microvasc Res 35: 122-131, 1988[ISI][Medline].

92.   Kennedy, C, and Leff P. How should P2X purinoceptors be classified pharmacologically? Trends Physiol Sci 16: 168-174, 1995.

93.   Khattab, M, Hohage H, Hollah P, Rahn KH, and Schlatter E. Effects of diadenosine polyphosphates on systemic and regional hemodynamics in anesthetized rats. Kidney Blood Press Res 21: 42-49, 1998[ISI][Medline].

94.   King, BF, Townsend-Nicholson A, and Burnstock G. Metabotropic receptors for ATP and UTP: exploring the correspondence between native and recombinant nucleotide receptors. Trends Pharmacol Sci 19: 506-514, 1998[ISI][Medline].

95.   Kishore, BK, Ginns SM, Krane CM, Nielsen S, and Knepper MA. Cellular localization of P2Y2 purinoceptor in rat renal inner medulla and lung. Am J Physiol Renal Physiol 278: F43-F51, 2000[Abstract/Free Full Text].

96.   Kleta, R, Hirsch J, Heindenreich S, Schlüter H, Zidek W, and Schlatter E. Effects of diadenosine polyphosphates, ATP and angiotensin II on membrane voltage and membrane conductances of rat mesangial cells. Pflügers Arch 430: 713-720, 1995[ISI][Medline].

97.   Kunapuli, SP, and Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J 336: 513-523, 1998[ISI][Medline].

98.   Levens, N, Beil M, and Jarvis M. Renal actions of a new adenosine agonist, CGS 21680A, selective for the A2 receptor. J Pharmacol Exp Ther 257: 1005-1012, 1991[Abstract].

99.   Levens, N, Beil M, and Schulz R. Intrarenal actions of the new adenosine agonist CGS 21680A, selective for the A2 receptor. J Pharmacol Exp Ther 257: 1013-1019, 1991[Abstract].

100.   Luthje, J, and Ogilvie A. The presence of diadenosine 5',5'''-P1,P3-triphosphate (Ap3A) in human platelets. Biochem Biophys Res Commun 115: 253-260, 1983[ISI][Medline].

101.   Majid, DSA, Inscho EW, and Navar LG. P2 purinoceptor saturation by adenosine triphosphate impairs renal autoregulation in dogs. J Am Soc Nephrol 10: 492-498, 1999[Abstract/Free Full Text].

102.   Majid, DSA, and Navar LG. Suppression of blood flow autoregulation plateau during nitric oxide blockade in canine kidney. Am J Physiol Renal Fluid Electrolyte Physiol 262: F40-F46, 1992[Abstract/Free Full Text].

103.   Malam-Souley, R, Seye C, Gadeau AP, Loirand G, Pillois X, Campan M, Pacaud P, and Desgranges C. Nucleotide receptor P2u partially mediates ATP-induced cell cycle progression of aortic smooth muscle cells. J Cell Physiol 166: 57-65, 1996[ISI][Medline].

104.   Marraccini, P, Fedele S, Marzilli M, Orsini E, Dukic G, Serasini L, and L'Abbate A. Adenosine-induced renal vasoconstriction in man. Cardiovasc Res 32: 949-953, 1996[ISI][Medline].

105.   Marraccini, P, Fedele S, Orsini E, Gliozheni E, Djukic G, Mazzarisi A, Serasini L, Marzilli M, and L'Abbate A. Adenosine and angiotensin system interact in the regulation of renal microcirculation in humans. J Cardiovasc Pharmacol 35: 758-762, 2000[ISI][Medline].

106.   Mitchell, KD, and Navar LG. Modulation of tubuloglomerular feedback responsiveness by extracellular ATP. Am J Physiol Renal Fluid Electrolyte Physiol 264: F458-F466, 1993[Abstract/Free Full Text].

107.   Mozaffari, MS, Abebe W, and Warren BK. Renal adenosine A3 receptors in the rat: assessment of functional role. Can J Physiol Pharmacol 78: 428-432, 2000[ISI][Medline].

108.   Mulryan, K, Gitterman DP, Lewis CJ, Vial C, Leckle BJ, Cobb AL, Brown JE, Conley EC, Buell G, Pritchard CA, and Evans RJ. Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 403: 86-89, 2000[ISI][Medline].

109.   Murray, RD, and Churchill PC. Effects of adenosine receptor agonists in the isolated, perfused rat kidney. Am J Physiol Heart Circ Physiol 247: H343-H348, 1984[Abstract/Free Full Text].

110.   Murray, RD, and Churchill PC. Concentration dependency of the renal vascular and renin secretory responses to adenosine receptor agonists. J Pharmacol Exp Ther 232: 1-5, 1985[Abstract].

111.   Navar, LG, Inscho EW, Majid DSA, Imig JD, Harrison-Bernard LM, and Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 76: 425-536, 1996[Abstract/Free Full Text].

112.   Nawa, G, Urano T, Tokino T, Ochi T, and Miyoshi Y. Cloning and characterization of the murine P2XM receptor gene. J Hum Genet 43: 262-267, 1998[ISI][Medline].

113.   Needleman, P, Minkes MS, and Douglas JR. Stimulation of prostaglandin biosynthesis by adenine nucleotides. Circ Res 34: 455-460, 1974[ISI][Medline].

114.   Nishiyama, A, Majid DSA, Taher KA, Miyatake A, and Navar LG. Relation between renal interstitial ATP concentrations and autoregulation-mediated changes in renal vascular resistance. Circ Res 86: 656-662, 2000[Abstract/Free Full Text].

115.   Nishiyama, A, Miura K, Miyatake A, Fujisawa Y, Yue W, Fukui T, Kimura S, and Abe Y. Renal interstitial concentration of adenosine during endotoxin shock. Eur J Pharmacol 385: 209-216, 1999[ISI][Medline].

116.   North, RA, and Surprenant A. Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 40: 563-580, 2000[ISI][Medline].

117.   Ogilvie, A, Bläsius R, Schulze-Lohoff E, and Sterzel RB. Adenine dinucleotides: a novel class of signalling molecules. J Auton Pharmacol 16: 325-328, 1996[ISI][Medline].

118.   Olsson, RA. Adenosine receptors in the cardiovascular system. Drug Dev Res 39: 301-307, 1996[ISI].

119.   Olsson, RA, and Pearson JD. Cardiovascular purinoceptors. Physiol Rev 70: 761-845, 1990[Free Full Text].

120.   Ongini, E, and Fredholm BB. Pharmacology of adenosine A2A receptors. Trends Pharmacol Sci 17: 364-372, 1996[ISI][Medline].

121.   Osswald, H, Muhlbauer B, and Schenk F. Adenosine mediates tubuloglomerular feedback response: an element of metabolic control of kidney function. Kidney Int 39, Suppl32: S-128-S-131, 1991.

122.   Osswald, H, Schmitz HJ, and Kemper R. Renal action of adenosine: effect on renin secretion in the rat. Naunyn Schmiedeberg's Arch Pharmacol 303: 95-99, 1978[ISI][Medline].

123.   Paulais, M, Baudouin-Legros M, and Teulon J. Extracellular ATP and UTP trigger calcium entry in mouse cortical thick ascending limbs. Am J Physiol Renal Fluid Electrolyte Physiol 268: F496-F502, 1995[Abstract/Free Full Text].

124.   Pavenstädt, H, Gloy J, Leipziger J, Klär B, Pfeilschifter J, Schollmeyer P, and Greger R. Effect of extracellular ATP on contraction, cytosolic calcium activity, membrane voltage, and ion currents of rat mesangial cells in primary culture. Br J Pharmacol 109: 953-959, 1993[Abstract].

125.   Pavenstädt, H, Henger A, Briner V, Greger R, and Schollmeyer P. Extracellular ATP regulates glomerular endothelial cell function. J Auton Pharmacol 16: 389-391, 1996[ISI][Medline].

126.   Pavenstädt, H, Späth M, Schlunk G, Nauck M, Fischer R, Wanner C, and Schollmeyer P. Effect of nucleotides on the cytosolic free calcium activity and inositol phospahtes in human glomerular epithelial cells. Br J Pharmacol 107: 189-195, 1992[Abstract].

127.   Pearson, JD, and Gordon JL. Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. Nature 281: 384-386, 1979[ISI][Medline].

128.   Pfeilschifter, J. Comparison of extracellular ATP and UTP signalling in rat renal mesangial cells. Biochem J 272: 469-472, 1990[ISI][Medline].

129.   Pfeilschifter, J. Extracellular ATP stimulates polyphosphoinositide hydrolysis and prostaglandin synthesis in rat renal mesangial cells. Cell Signal 2: 129-138, 1990[ISI][Medline].

130.   Pfeilschifter, J, Huwiler A, and Briner VA. Proliferative mechanisms in kidney cells. Curr Opin Nephrol Hypertension 4: 98-103, 1995[Medline].

131.   Pfeilschifter, J, and Merriweather C. Extracellular ATP and UTP activation of phospholipase D is mediated by protein kinase C-epsilon in rat renal mesangial cells. Br J Pharmacol 110: 847-853, 1993[Abstract].

132.   Pflueger, AC, Schenk F, and Osswald H. Increased sensitivity of the renal vasculature to adenosine in streptozotocin-induced diabetes mellitus rats. Am J Physiol Renal Fluid Electrolyte Physiol 269: F529-F535, 1995[Abstract/Free Full Text].

133.   Prior, HM, Yates MS, and Beech DJ. Role of K+ channels in A2A adenosine receptor-mediated dilation of the pressurized renal arcuate artery. Br J Pharmacol 126: 494-500, 1999[Abstract/Free Full Text].

134.   Ralevic, V. P2 receptors in the central and peripheral nervous systems modulating sympathetic vasomotor tone. J Auton Nerv Syst 81: 205-211, 2000[ISI][Medline].

135.   Ralevic, V, and Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492, 1998[Abstract/Free Full Text].

136.   Rubera, I, Tauc M, Bidet M, Verheecke-Mauze C, De Renzis G, Poujeol C, Cuiller A, and Poujeol P. Extracellular ATP increases [Ca2+]i in distal tubule cells. II. Activation of a Ca2+-dependent Cl- conductance. Am J Physiol Renal Physiol 279: F102-F111, 2000[Abstract/Free Full Text].

137.   Rump, LC, Bohmann C, Schwertfeger E, Krumme B, Von Kugelgen I, and Schollmeyer P. Extracellular ATP in the human kidney: mode of release and vascular effects. J Auton Pharmacol 16: 371-375, 1996[ISI][Medline].

138.   Rump, LC, Oberhauser V, and Von Kügelgen I. Purinoceptors mediate renal vasodilation by nitric oxide dependent and independent mechanisms. Kidney Int 54: 473-481, 1998[ISI][Medline].

139.   Schlatter, E, Ankorina I, Haxelmans S, and Kleta R. Effects of diadenosine polyphosphates, ATP and angiotensin II on cytosolic Ca2+ activity and contraction of rat mesangial cells. Eur J Physiol 430: 721-728, 1995[ISI][Medline].

140.   Schlatter, E, Haxelmans S, Ankorina I, and Kleta R. Regulation of Na+/H+ exchange by diadenosine polyphosphates, angiotensin II and vasopressin in rat cortical collecting duct. J Am Soc Nephrol 6: 1223-1229, 1995[Abstract].

141.   Schlüter, H, Offers E, Brüggemann G, Van der Giet M, Tepel M, Nordhoff W, Karas M, Spieker C, Witzel H, and Zidek W. Diadenosine phosphates and the physiological control of blood pressure. Nature 367: 186-188, 1994[ISI][Medline].

142.   Schlüter, H, Tepel M, and Zidek W. Vascular actions of diadenosine phosphates. J Auton Pharmacol 16: 357-362, 1996[ISI][Medline].

143.   Schnermann, J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol Regulatory Integrative Comp Physiol 274: R263-R279, 1998[Abstract/Free Full Text].

144.   Schulte, EA, Hohendahl A, Stegeman H, Hirsch JR, Saleh H, and Schlatter E. Natriuretic peptides and diadenosine polyphosphates modulate pH regulation of rat mesangial cells. Cell Physiol Biochem 9: 310-322, 1999[ISI][Medline].

145.   Schulze-Lohoff, E, Bitzer M, Ogilvie A, and Sterzel RB. P2U-purinergic receptor activation mediates inhibition of cAMP accumulation in cultured renal mesangial cells. Renal Physiol Biochem 18: 219-230, 1995[ISI][Medline].

146.   Schulze-Lohoff, E, Hugo C, Rost S, Arnold S, Gruber A, Brüne B, and Sterzel RB. Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. Am J Physiol Renal Physiol 275: F962-F971, 1998[Abstract/Free Full Text].

147.   Schulze-Lohoff, E, Ogilvie A, and Sterzel RB. Extracellular nucleotides as signalling molecules for renal mesangial cells. J Auton Pharmacol 16: 381-384, 1996[ISI][Medline].

148.   Schulze-Lohoff, E, Zanner S, Ogilvie A, and Sterzel RB. Extracellular ATP stimulates proliferation of cultured mesangial cells via P2-purinergic receptors. Am J Physiol Renal Fluid Electrolyte Physiol 263: F374-F383, 1992[Abstract/Free Full Text].

149.   Schwartz, DD, and Malik KU. Renal periarterial nerve stimulation-induced vasoconstriction at low frequencies is primarily due to release of a purinergic transmitter in the rat. J Pharmacol Exp Ther 250: 764-771, 1989[Abstract].

150.   Schwiebert, EM, and Kishore BK. Extracellular nucleotide signaling along the renal epithelium. Am J Physiol Renal Physiol 280: F945-F963, 2001[Abstract/Free Full Text].

151.   Simon, J, Kidd EJ, Smith FM, Chessell IP, Murrell-Lagnado RD, Humphrey PPA, and Barnard EA. Localization and functional expression of splice variants of the P2X2 receptor. Mol Pharmacol 52: 237-248, 1997[Abstract/Free Full Text].

152.   Siragy, H, and Linden J. Sodium intake markedly alters renal interstitial fluid adenosine. Hypertension 27: 404-407, 1996[Abstract/Free Full Text].

153.   Skott, O, and Baumbach L. Effects of adenosine on renin release from isolated rat glomeruli and kidney slices. Pflügers Arch 404: 232-237, 1985[ISI][Medline].

154.   Suko, Y, Kawahara K, Fukuda Y, and Masuda Y. Nuclear and cytosolic calcium signaling induced by extracellular ATP in rat kidney inner medullary collecting duct cells. Biochem Biophys Res Commun 234: 224-229, 1997[ISI][Medline].

155.   Takeda, M, Kawamura T, Kobayashi M, and Endou H. ATP-induced calcium mobilization in glomerular mesangial cells is mediated by P2u purinoceptor. Biochem Mol Biol Int 39: 1193-1200, 1996[ISI][Medline].

156.   Takeda, M, Kobayashi M, and Endou H. Establishment of a mouse clonal early proximal tubule cell line and outer medullary collecting duct cells expressing P2 purinoceptors. Biochem Mol Biol Int 44: 657-664, 1998[ISI][Medline].

157.   Tamesue, S, Sato C, and Katsuragi T. ATP release caused by bradykinin, substance P and histamine from intact and cultured smooth muscles of guinea-pig vas deferens. Naunyn Schmiedebergs Arch Pharmacol 357: 240-244, 1998[ISI][Medline].

158.   Tang, LL, Parker M, Fei Q, and Loutzenhiser R. Afferent arteriolar adenosine A2a receptors are coupled to KATP in in vitro perfused hydronephrotic rat kidney. Am J Physiol Renal Physiol 277: F926-F933, 1999[Abstract/Free Full Text].

159.   Taylor, AL, Kudlow BA, Marrs KL, Gruenert DC, Guggino WB, and Schwiebert EM. Bioluminescence detection of ATP release mechanisms in epithelia. Am J Physiol Cell Physiol 275: C1391-C1406, 1998[Abstract/Free Full Text].

160.   Tepel, M, Heidenreich S, Schlüter H, Beinlich A, Nofer JR, Walter M, Assmann G, and Zidek W. Diadenosine polyphosphates induce transplasma membrane calcium influx in cultured glomerular mesangial cells. Eur J Clin Invest 26: 1077-1084, 1996[ISI][Medline].

161.   Tepel, M, Jankowski J, Schlüter H, Bachmann J, Van der Giet M, Ruess C, Terliesner J, and Zidek W. Diadenosine polyphosphates' action on calcium and vessel contraction. Am J Hypertens 10: 1404-1410, 1997[ISI][Medline].

162.   Thomson, SC, Bao DJ, Deng A, and Vallon V. Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback. J Clin Invest 106: 289-298, 2000[Abstract/Free Full Text].

163.   Valera, S, Hussy N, Evans RJ, Adaml N, North RA, Surprenant A, and Buell G. A new class of a ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature 371: 516-519, 1994[ISI][Medline].

164.   Van der Giet, M, Cinkilic O, Jankowski J, Tepel M, Zidek W, and Schlüter H. Evidence for two different P2X-receptors mediating vasoconstriction of Ap5A and Ap6A in the isolated perfused rat kidney. Br J Pharmacol 127: 1463-1469, 1999[Abstract/Free Full Text].

165.   Van der Giet, M, Jankowski J, Schlüter H, Zidek W, and Tepel M. Mediation of the vasoactive properties of diadenosine tetraphosphate via various purinoceptors. J Hypertens 16: 1939-1943, 1998[ISI][Medline].

166.   Van der Giet, M, Khattab M, Börgel J, Schlüter H, and Zidek W. Differential effects of diadenosine phosphates on purinoceptors in the rat isolated perfused kidney. Br J Pharmacol 120: 1453-1460, 1997[Abstract].

167.   Vargas, F, Moreno MRR, and Osuna A. Renal vascular reactivity to ATP in ageing rats. Med Sci Res 24: 263-265, 1996[ISI].

168.   Vargas, F, Osuna A, and Fernández-Rivas A. Renal vascular reactivity to ATP in hyper- and hypothyroid rats. Experientia 52: 225-229, 1996[ISI][Medline].

169.   Von Kügelgen, I, Krumme B, Schaible U, Schollmeyer PJ, and Rump LC. Vasoconstrictor responses to the P2x-purinoceptor agonist beta ,gamma -methylene-L-ATP in human cutaneous and renal blood vessels. Br J Pharmacol 116: 1932-1936, 1995[Abstract].

170.   Wang, DJ, Huang NN, and Hepple LA. Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cells. J Cell Physiol 1532: 221-233, 1992.

171.   Weihprecht, H, Lorenz JN, Briggs JP, and Schnermann J. Vasomotor effects of purinergic agonists in isolated rabbit afferent arterioles. Am J Physiol Renal Fluid Electrolyte Physiol 263: F1026-F1033, 1992[Abstract/Free Full Text].

172.   Weihprecht, H, Lorenz JN, Briggs JP, and Schnermann J. Synergistic effects of angiotensin and adenosine in the renal microvasculature. Am J Physiol Renal Fluid Electrolyte Physiol 266: F227-F239, 1994[Abstract/Free Full Text].

173.   White, SM, Imig JD, and Inscho EW. Calcium signaling pathways utilized by P2X receptors in preglomerular MVSMC. Am J Physiol Renal Physiol 280: F1054-F1061, 2001[Abstract/Free Full Text].

174.   Wildman, SS, Brown SG, King BF, and Burnstock G. Selectivity of diadenosine polyphosphates for rat P2X receptor subunits. Eur J Pharmacol 367: 119-123, 1999[ISI][Medline].

175.   Wong, PSK, and Johns EJ. The action of angiotensin II on the intracellular sodium content of suspensions of rat proximal tubules. J Physiol (Lond) 497: 219-227, 1996[Abstract].

176.   Yamada, H, Seki G, Taniguchi S, Uwatoko S, Suzuki K, and Kurokawa K. Mechanism of [Ca2+]i increase by extracellular ATP in isolated rabbit renal proximal tubules. Am J Physiol Cell Physiol 270: C1096-C1104, 1996[Abstract/Free Full Text].


Am J Physiol Renal Fluid Electrolyte Physiol 280(6):F927-F944
0363-6127/01 $5.00 Copyright © 2001 the American Physiological Society